Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (XLPADTRACE)

This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring intermittent claudication, randomized controlled trial Read More

Pre-screening criteria

• Laboratory values available ≤ 1 year of the date of screening: hemoglobin ≥9g, platelet count >50,000 mm3 or <600,000 mm3
• No history of stroke or transient ischemic attack (TIA)
• No allergy to aspirin
• ≥40 years of age

• Presence of documented PAD by ABI <0.80 at rest or ≥20% drop in claudication limited exercise ABI in any limb and one of the following criteria in the corresponding limb:

  i.Prior surgical and/or endovascular lower extremity intervention (infra-renal aorta to pedal arteries) ii. Known presence of flow-limiting stenosis (≥70%) by clinically indicated angiography, computed tomographic (CT) or magnetic resonance imaging (MRI) tests or by Duplex ultrasonography (DUS) defined standard clinical criteria in lower extremity arteries

• Documented IC Rutherford/Becker (RC) category ≥2
• Presence of any one of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), lipid lowering therapy, aspirin and beta-blocker drugs]-No MI or percutaneous coronary intervention (PCI) with DES within the past 11 months
• No planned surgical or endovascular procedures other than for the treatment of IC for the expected duration of the study
• No warfarin or other chronic oral anticoagulant use within the last 14 days
• No use of ticagrelor, clopidogrel, prasugrel or ticlopidine within last 7 days
• No contraindication(s) to the use of antithrombin or antiplatelet agents (history of intra-cerebral hemorrhage or ICH, presence of intracerebral mass, recent or <12 weeks gastrointestinal bleed requiring blood transfusion, any blood transfusion within the last 6 weeks, any trauma requiring surgery within the last 4 weeks or any surgical or endovascular procedure within the last 4 weeks
• No use of cilostazol and/or pentoxyphilline within last 7 days
• Severe psychiatric or behavioral illness that in the judgement of the investigator precludes study participation
• No history of major or minor amputation
• Severe heart, vascular and lung disease in the discretion of the investigator that precludes study participation.
• Ability to walk for at least 15 min/day, at least 3 days/week, at ≥20 steps/min

Inclusion criteria

• Treadmill PWT= 2-10 min on Gardner protocol
• Estimated survival ≥1 year in the judgment of the site investigator
• Use of at least one aspirin dose within at least 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose prior to randomization at 81 mg dose in patients on chronic (>5 days) aspirin therapy (at clinically indicated doses).
• Presence of any one of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), lipid lowering therapy, aspirin and beta-blocker drugs]

Exclusion Criteria:

• MI or percutaneous coronary intervention (PCI) with DES within the past 11 months
• Positive pregnancy test
• Planned surgical or endovascular procedures other than for the treatment of IC
• Warfarin or other chronic oral anticoagulant use within 14 days
• Use of Ticagrelor, Clopidogrel, Prasugrel or Ticlopidine within 7 days
• Contraindication(s) to the use of antithrombin or antiplatelet agents (history of intra-cerebral hemorrhage or ICH, presence of intracerebral mass, recent or <12 weeks gastrointestinal bleed requiring blood transfusion, any blood transfusion within the last 6 weeks, any trauma requiring surgery within the last 4 weeks or any surgical or endovascular procedure within the last 4 weeks
• Use of cilostazol and/or pentoxyphilline within 7 days